Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.22 USD
+0.04 (3.39%)
Updated Sep 10, 2024 03:48 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Nektar Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -276.06 | -368.20 | -523.84 | -444.44 | -440.67 |
Depreciation/Amortization & Depletion | 84.32 | 13.03 | 20.88 | 14.18 | 13.16 |
Net Change from Assets/Liabilities | -19.80 | 0.49 | -23.08 | 16.71 | 21.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.93 | 50.67 | 113.38 | 100.26 | 77.14 |
Net Cash From Operating Activities | -192.61 | -304.01 | -412.66 | -313.29 | -328.68 |
Property & Equipment | 0.38 | 7.52 | -14.99 | -7.26 | -26.29 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 139.18 | 358.32 | 217.77 | 503.47 | 233.17 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 139.56 | 365.84 | 202.78 | 496.21 | 206.89 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.03 | 0.76 | 33.24 | 23.40 | 23.36 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -250.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.75 | 3.00 | 146.25 | 0.00 |
Net Cash from Financing Activities | 0.03 | 1.51 | 36.24 | -80.35 | 23.36 |
Effect of Exchange Rate Changes | 0.06 | -0.33 | -0.09 | 0.02 | -0.10 |
Net Change In Cash & Equivalents | -52.95 | 63.01 | -173.74 | 102.59 | -98.54 |
Cash at Beginning of Period | 88.23 | 25.22 | 198.96 | 96.36 | 194.91 |
Cash at End of Period | 35.28 | 88.23 | 25.22 | 198.96 | 96.36 |
Diluted Net EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 |
Fiscal Year End for Nektar Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -89.17 | -36.80 | -276.06 | -233.98 | -188.14 |
Depreciation/Amortization & Depletion | -2.58 | -1.46 | 84.32 | 70.53 | 72.82 |
Net Change from Assets/Liabilities | 4.18 | -6.62 | -19.80 | -15.07 | -10.58 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.97 | -3.01 | 18.93 | 32.96 | 22.47 |
Net Cash From Operating Activities | -85.59 | -47.89 | -192.61 | -145.56 | -103.44 |
Property & Equipment | -0.34 | -0.16 | 0.38 | 0.62 | -0.60 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 36.58 | 19.42 | 139.18 | 121.56 | 66.36 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 36.24 | 19.26 | 139.56 | 122.18 | 65.77 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 27.02 | 27.00 | 0.03 | 0.02 | 0.02 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 15.00 | 15.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 42.02 | 42.00 | 0.03 | 0.02 | 0.02 |
Effect of Exchange Rate Changes | -0.01 | -0.01 | 0.06 | 0.05 | 0.15 |
Net Change In Cash & Equivalents | -7.34 | 13.37 | -52.95 | -23.31 | -37.50 |
Cash at Beginning of Period | 35.28 | 35.28 | 88.23 | 88.23 | 88.23 |
Cash at End of Period | 27.94 | 48.64 | 35.28 | 64.92 | 50.73 |
Diluted Net EPS | -0.25 | -0.19 | -0.21 | -0.24 | -0.27 |